A Prospective and Randomized Controlled Trial of Empirical Formula of Traditinal Chinease Medicine in Treating Chronic Heart Failure

Chinese Academy of Medical Sciences Fuwai Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Aged 18 to 75 years;
•2. Patients who meet the diagnostic criteria of Western medicine for coronary heart disease, elective patients within two weeks after DCB surgery;
•3. Voluntary selection of patients who undergo coronary angiography 12 months after surgery;
•4. Meet the TCM criteria for syndrome differentiation of Qi deficiency and blood stasis (total score >=8 points, and secondary symptoms >= 4 points);
•5. The subjects voluntarily participated in the trial and signed the informed consent.

•1. Heart valve disease, congenital heart disease, aortic dissection or aortic aneurysm requiring surgical or interventional treatment;
•2. Hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, active myocarditis, infective endocarditis, constrictive pericarditis or other pericardial diseases;
•3. Patients with malignant arrhythmia and poorly controlled hypertension;
•4. Cardiac synchronization therapy within 3 months; cardiac PCI, CABG and other major vascular surgery or acute coronary syndrome within 1 month;
•5. Cerebrovascular events such as old stroke and transient cerebral ischemia occurred within 6 months;
•6. Patients with serious primary diseases and dysfunctions of the lung, liver, kidney, hematopoietic system, immune system, etc.;
•7. Subjects who participated in other drug clinical trials or interventional studies within the first four weeks of this trial;
•8. Patients with serious primary diseases and dysfunctions of the lung, liver, kidney, hematopoietic system, immune system, etc.;
•9. Subjects who participated in other drug clinical trials or interventional studies within the first four weeks of this trial;
•10. Those who are deemed unsuitable to participate in clinical trials by the investigator.

发起方

Chinese Academy of Medical Sciences Fuwai Hospital